San Francisco Department of Public Health

Grant Colfax, MD Director of Health



March 20, 2020

Linda Wong Clerk of the Budget & Finance Committee Board of Supervisors 1 Dr. Carlton B. Goodlett Place, Room 244 San Francisco, CA 94102-4689

Dear Ms. Wong:

This is to respond to your email of March 20, 2020, requesting a written explanation for why the contracts subject to approval by the Board of Supervisors are retroactive. As noted, the Department is requesting retroactive contract approval for the following two items:

- File No. 200012 Agreement Retroactive McKesson Corporation Group Purchasing Distribution of Pharmaceuticals Not to Exceed \$381,382,991; and
- File No. 200013 Agreement Retroactive McKesson Plasma and Biologics LLC Pharmaceuticals, Biologics and Specialty Drugs Not to Exceed \$295,934,790.

These two resolutions were approved by the Board of Supervisors Budget and Finance Committee on February 12, 2020, with the start date of each contract proposed for February 1, 2020. Completion of the proposed contract language, including specific new terms, was linked to finalizing the language for an amendment to Administrative Code 21 (Sections 21A.1 and 21A.2) which allowed the inclusion of this specific language in each contract.

The Department worked collaboratively with the City Attorney's Office to align the contract start dates to the revised ordinance approval date, however, finalizing the language of ordinance 33-20 took longer to complete than anticipated at the City Attorney's Office. This process, in turn, delayed the Department's ability to seek Board of Supervisors approval for the proposed contracts.

Ordinance 33-20 was finally passed by the Board of Supervisors on February 11, 2020, and signed by the Mayor on February 21, 2020 (File 191237). After signature by the Mayor, the ordinance was held under the 30 day rule prior to enactment. The Department was advised by the City Attorney's Office that these resolutions could not be heard by the full Board of Supervisors until ordinance 33-20 went into effect, which brings us to the upcoming meeting.

The Department is happy to respond to any further questions. The timing issue was discussed in detail with the Board of Supervisor Budget and Legislative Analyst, and at the Budget and Finance Committee on February 12, 2020, prior to the Committee's approval, should further reference be helpful.

Please note that both of these distributors are long-time existing DPH vendors, currently operating under the purchase order process. The Department will continue purchasing pharmaceuticals under the current process until such time as the new contracts are approved. There will be no retroactive payments under the proposed new contracts, as all current spending up until the proposed new contracts are certified will occur under the existing process.

Linda Wong, Clerk of the Budget & Finance Committee Board of Supervisors March 20, 2020 Page 2

For questions on this matter, please contact me at (415) 255-3404, <u>Michelle.Ruggels@SFDPH.org</u>, or Robert Longhitano, at <u>robert.longhitano@sfdph.org</u>.

Sincerely,

Mc What have the second of the s

Michelle Ruggels

Director

DPH Business Office

cc: Grant Colfax, M.D., Director of Health

Greg Wagner, Chief Financial Officer, DPH

Jacquie Hale, Manager, DPH Office of Contract Management and Compliance

Rob Longhitano, Manager, DPH Office of Contract Management and Compliance